Alzheimer's Disease Trial, By Invitation NCT06826157 Sponsor: IRCCS San Raffaele Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, By Invitation

NCT06826157
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Participants must be right-handed.
  • Participants must be monolingual native Italian speakers.
  • Participants must be between 50 and 85 years old.
  • Participants must have normal vision, or vision that is fully corrected with glasses or contact lenses.
  • Participants must give written and verbal consent to take part in the study.
  • Participants taking psychiatric medications (such as benzodiazepines, antipsychotics, or antidepressants) must have been on a stable dose for more than 4 weeks.
  • Participants may have a diagnosis of amnestic Mild Cognitive Impairment (a specific type of early memory difficulty).
  • Participants with amnestic MCI must score 24 or above on a standard memory and thinking test called the MMSE.
  • Participants with amnestic MCI who are taking certain memory medications (such as galantamine, rivastigmine, donepezil, or memantine) must have been on a stable dose for more than 4 weeks.
  • Participants with amnestic MCI must have available results from a cerebrospinal fluid (brain and spinal fluid) test for Alzheimer's disease markers.
  • Participants may have a diagnosis of Alzheimer's disease dementia, Frontotemporal Dementia (FTD), or Lewy Body Dementia (LBD).
  • Participants with Alzheimer's disease dementia, FTD, or LBD must score 15 or above on the MMSE.
  • Participants with Alzheimer's disease dementia, FTD, or LBD who are taking certain memory medications (such as galantamine, rivastigmine, donepezil, or memantine) must have been on a stable dose for more than 4 weeks.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose cognitive (thinking and memory) problems are caused by a known secondary condition, based on their medical history, neurological examination, or brain imaging results.
  • People experiencing very rapid cognitive decline happening over weeks or months, which may suggest a serious condition such as prion disease, a brain tumour, or a metabolic disorder.
  • People with a history of other significant systemic illness (including cancer diagnosed in the last 3 years or abnormal liver or kidney function), neurological conditions (including epilepsy), psychiatric illness, head injury, heart events, or blood vessel changes in the brain.
  • People with a history of alcohol or psychotropic drug abuse.
  • People who are enrolled in another clinical trial testing disease-modifying drugs for Alzheimer's disease during the study period.
  • People who have a cardiac pacemaker or other types of cardiac catheters, which are not compatible with MRI scanning.
  • People who have metal splinters or fragments in their body, which are not compatible with MRI scanning.
  • People who have metal prostheses that are not compatible with the magnetic field used in MRI scanning.
  • People who have claustrophobia (fear of enclosed spaces), which would prevent MRI scanning.
  • Women who are pregnant, planning to become pregnant during the study, or who are currently breastfeeding.
  • For healthy control participants: people with a history of significant systemic illness (including cancer in the last 3 years or abnormal liver or kidney function), neurological conditions (including epilepsy), psychiatric illness, head injury, heart events, or blood vessel changes in the brain.
  • For healthy control participants: people with a history of alcohol or psychotropic drug abuse.
  • For healthy control participants: people with contraindications to MRI scanning (as listed above).
  • For healthy control participants: women who are pregnant, planning to become pregnant during the study, or who are currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
IRCCS San Raffaele
Registry
ClinicalTrials.gov
Start date
5 November 2021
Est. completion
15 April 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Cortical source densities in resting-state EEG for mild cognitive impairment: Markers of differential diagnosis and dementia conversion prediction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov